首站-论文投稿智能助手
典型文献
Diabetes mellitus promoted lymph node metastasis in gastric cancer: a 15-year single-institution experience
文献摘要:
Background::Previous studies have revealed that diabetes mellitus (DM) promotes disease progress of gastric cancer (GC). This study aimed to further investigating whether DM advanced lymph nodes (LNs) metastasis in GC.Methods::The clinicopathologic data of GC patients with >15 examined LN (ELN) between October 2004 and December 2019 from a prospectively maintained database were included. The observational outcomes included the number (N3b status) and anatomical distribution (N3 stations) of metastatic LN (MLN).Results::A total of 2142 eligible patients were included in the study between October 2004 and December 2019. N3 stations metastasis (26.8% in DM vs. 19.3% in non-DM, P = 0.026) and N3b status (18.8% in DM vs. 12.8% in non-DM, P = 0.039) were more advanced in the DM group, and multivariate logistic regression analyses confirmed that DM was an independent factor of developing N3 stations metastasis (odds ratio [OR] = 1.771, P= 0.011) and N3b status (OR= 1.752, P= 0.028). Also, multivariate analyses determined DM was independently associated with more MLN (β = 1.424, P = 0.047). The preponderance of N3 stations metastasis (DM vs. non-DM, T1-2: 2.2% vs. 4.9%, T3: 29.0% vs. 20.3%, T4a: 38.9% vs. 25.8%, T4b: 50.0% vs. 36.6%; ELN16-29: 8.6% vs. 10.4%, ELN30-44: 27.9% vs. 20.5%, ELN ≥ 45: 37.7% vs. 25.3%), N3b status (DM vs. non-DM, T1-2: 0% vs. 1.7%, T3: 16.1% vs. 5.1%, T4a: 27.8% vs. 19.1%, T4b: 44.0% vs. 28.0%; ELN16-29: 8.6% vs. 7.9%, ELN30-44: 18.0% vs. 11.8%, ELN ≥ 45: 26.4% vs. 17.3%), and the number of MLN (DM vs. non-DM, T1-2: 0.4 vs. 1.1, T3: 8.6 vs. 5.2, T4a: 9.7 vs. 8.6, T4b: 17.0 vs. 12.8; ELN16-29: 3.6 vs. 4.6, ELN30-44: 5.8 vs. 5.5, ELN ≥ 45: 12.0 vs. 7.7) of DM group increased with the advancement of primary tumor depth stage and raising of ELN. Conclusions::DM was an independent risk factor for promoting LN metastasis. The preponderance of LN involvement in the DM group was aggravated with the advancement of tumor depth.
文献关键词:
Diabetes mellitus;Gastric cancer;Lymph node;Metastasis
作者姓名:
Chen Xinhua;Chen Yuehong;Li Tao;Liang Weiqi;Huang Huilin;Su Hongtao;Sui Chuyang;Hu Yanfeng;Chen Hao;Lin Tian;Chen Tao;Zhao Liying;Liu Hao;Li Guoxin;Yu Jiang
作者机构:
Department of General Surgery & Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, The First School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong 510515, China
引用格式:
[1]Chen Xinhua;Chen Yuehong;Li Tao;Liang Weiqi;Huang Huilin;Su Hongtao;Sui Chuyang;Hu Yanfeng;Chen Hao;Lin Tian;Chen Tao;Zhao Liying;Liu Hao;Li Guoxin;Yu Jiang-.Diabetes mellitus promoted lymph node metastasis in gastric cancer: a 15-year single-institution experience)[J].中华医学杂志(英文版),2022(08):950-961
A类:
ELN16,ELN30
B类:
Diabetes,mellitus,promoted,lymph,metastasis,gastric,cancer,year,single,institution,experience,Background,Previous,studies,have,revealed,that,diabetes,DM,promotes,disease,progress,This,study,aimed,further,investigating,whether,advanced,nodes,LNs,Methods,clinicopathologic,patients,examined,between,October,December,from,prospectively,maintained,database,were,included,observational,outcomes,number,N3b,status,anatomical,distribution,stations,metastatic,MLN,Results,total,eligible,more,group,multivariate,logistic,regression,analyses,confirmed,was,developing,odds,ratio,Also,determined,independently,associated,preponderance,T4a,T4b,increased,advancement,primary,tumor,depth,stage,raising,Conclusions,risk,promoting,involvement,aggravated,Gastric,Lymph,Metastasis
AB值:
0.391916
相似文献
Prognostic role of plasma levels of γ-glutamyl transpeptidase in patients with advanced gastric cancer treated with anti-PD-1 immunotherapy
Shaojie Xu;Yiming Feng;Xingyin Li;Zaozao Huang;Hewei Li;Ganxin Wang-First Clinical College,Huazhong University of Science and Technology,Wuhan 430022,China;Department of Radiology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China;Yangchunhu Community Hospital,Liyuan Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430077,China;Department of Orthopedics,Liyuan Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430077,China;Cancer Center,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China
Knowledge about,attitude and acceptance towards,and predictors of intention to receive the COVID-19 vaccine among cancer patients in Eastern China:A cross-sectional survey
Jing Hong;Xiao-wan Xu;Jing Yang;Jing Zheng;Shu-mei Dai;Ju Zhou;Qing-mei Zhang;Yi Ruan;Chang-quan Ling-School of Traditional Chinese Medicine,Naval Medical University,Shanghai 200433,China;Department of Integrative Oncology,Changhai Hospital,Naval Medical University,Shanghai 200433,China;Department of Oncology,The First Affiliated Hospital,Bengbu Medical College,Bengbu 233010,Anhui Province,China;Department of Nursing,Fuyang Cancer Hospital,Fuyang 236000,Anhui Province,China;Department of Cardiac Rehabilitation,Shanghai First Rehabilitation Hospital,Shanghai 200090,China;Department of Radiation Oncology,Anhui Chest Hospital,Hefei 230022,Anhui Province,China;Department of Anesthesiology,Chaohu Hospital,Anhui Medical University,Hefei 238000,Anhui Province,China
Clinical outcomes of atezolizumab in combination with etoposide/platinum for treatment of extensive-stage small-cell lung cancer:A real-world,multicenter,retrospective,controlled study in China
Hanxiao Chen;Xiangjuan Ma;Jie Liu;Yu Yang;Yong Fang;Liping Wang;Jian Fang;Jun Zhao;Minglei Zhuo-Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department Ⅰ of Thoracic Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department Ⅱ of Thoracic Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Department of Pneumology,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250117,China;Department of Oncology,the 2nd Affiliated Hospital of Harbin Medical University,Harbin 150001,China;Department of Oncology,Sir Run Run Shaw Hospital Zhejiang University School of Medicine,Hangzhou 310020,China;Department of Oncology,Baotou Cancer Hospital,Baotou 014030,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。